Advertising Policy

1. No naming of Schedule 4 substances

Australian law (Therapeutic Goods Act 1989, s 42DL and s 42DLB) prohibits direct-to-consumer advertising of Schedule 4 substances. Fusenite does not name any Schedule 4 substance in any consumer-facing advertising — this includes our website, paid social media, search ads, emails, SMS, podcasts, sponsorships, and influencer content.

2. No before/after weight or hair imagery

We do not use before-and-after photographs of weight loss or hair regrowth in our advertising, in line with ACCC and TGA guidance.

3. Testimonials

Patient testimonials are clearly disclosed as paid testimonials where applicable. Testimonials reference the patient’s experience of the programme — the support, the process, the team — never a specific medication. Every testimonial is accompanied by the required disclaimer.

4. No influencer endorsements of S4 medicines

We do not engage influencers to promote Schedule 4 medicines, in line with the TGA’s requirements for testimonials in valuable consideration.

5. No fake scarcity or countdowns

We do not advertise “only X spots left”, fake countdowns, or other manufactured urgency. Operational urgency (e.g. “reviewed within 24 hours”, “ships within 48 hours of approval”) is permitted because it’s truthful operationally.

6. Truthful pricing

Advertised prices are inclusive of programme fees. Where medication is invoiced separately at pharmacy passthrough, this is clearly stated alongside the programme price. We do not advertise headline prices that are not actually achievable.

7. Eligibility framing

We always pair eligibility messaging with a clear note that eligibility does not guarantee treatment, and that treatment is at the discretion of the clinician.

8. Accreditation and qualifications

We do not display accreditation badges (ISO 27001, ACHS, QIP, NSQPCH, LegitScript, etc.) until they are earned. AHPRA registration numbers for clinicians are only published once verified. We do not list qualifications a clinician does not hold.

9. Reporting concerns

If you believe any Fusenite advertising breaches the Therapeutic Goods Advertising Code or AHPRA guidelines, please email legal@fusenite.com — we investigate every report.